X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.fiercepharma.com/pharma/amgen-facing-potential-enbrel-price-cap-colorado-takes-states-new-drug-affordability-board
https://endpts.com/colorado-begins-process-to-potentially-set-payment-limit-on-amgens-arthritis-drug-enbrel/
https://www.ema.europa.eu/en/documents/overview/erelzi-epar-medicine-overview_en.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103795
https://www.reuters.com/markets/deals/amgen-set-buy-biotech-firm-horizon-26-bln-valuation-bloomberg-news-2022-12-12/?rpc=401&
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761042
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761042
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103795
https://www.crikey.com.au/2022/05/10/pfizer-sues-to-halt-rival-arthritis-drug/
https://www.fiercepharma.com/pharma/amgen-stalls-samsung-s-enbrel-biosim-until-2029-second-patent-win-year
https://www.nice.org.uk/news/article/nice-recommends-several-treatment-options-to-help-thousands-with-moderate-rheumatoid-arthritis#:~:text=NICE%20has%20today%20(10th,for%20use%20within%20the%20NHS.
https://www.globenewswire.com/news-release/2021/06/01/2239371/0/en/Biogen-and-Bio-Thera-Announce-Positive-Results-From-Phase-3-Study-of-BAT1806-a-Proposed-Biosimilar-Referencing-Actemra-Tocilizumab.html
https://www.reuters.com/business/healthcare-pharmaceuticals/us-supreme-court-snubs-novartis-appeal-over-arthritis-drug-enbrel-2021-05-17/
https://www.fiercepharma.com/pharma/sandoz-s-enbrel-biosim-case-turned-away-at-supreme-court-giving-amgen-s-blockbuster-many
https://www.bigmoleculewatch.com/2020/09/22/health-canada-approves-mercks-etanercept-biosimilar-for-new-indications/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+GoodwinProcter-BigMoleculeWatchBlog+%28Big+Molecule+Watch+Blog+%7C+Goodwin%29
https://www.bigmoleculewatch.com/2020/08/27/lupin-mylan-launch-etanercept-biosimilar-in-germany/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+GoodwinProcter-BigMoleculeWatchBlog+%28Big+Molecule+Watch+Blog+%7C+Goodwin%29
https://www.law360.com/lifesciences/articles/1297603?utm_source=rss&utm_medium=rss&utm_campaign=section
https://www.fiercepharma.com/pharma/could-amgen-test-enbrel-or-other-anti-tnf-drugs-against-covid-19-ceo-bradway-drops-a-hint
https://www.reuters.com/article/us-amgen-novartis-enbrel/amgen-defeats-novartis-appeal-over-arthritis-drug-enbrels-patents-idUSKBN2426EG
https://www.biopharmadive.com/news/amgen-novartis-enbrel-patent-appeal-court/580920/
https://www.sandoz.com/news/media-releases/sandoz-reviewing-options-after-federal-circuit-upholds-lower-court-ruling
http://investors.amgen.com/news-releases/news-release-details/appeals-court-affirms-validity-enbrelr-etanercept-patents
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761042
https://www.ema.europa.eu/documents/overview/nepexto-epar-medicine-overview_en.pdf
https://www.prnewswire.com/news-releases/mylan-and-lupin-receive-european-marketing-authorization-for-nepexto-biosimilar-etanercept-301070519.html
https://www.bigmoleculewatch.com/2020/05/11/aryogens-bevacizumab-biosimilar-be1040v-found-noninferior-to-avastin-in-phase-iii-study/
https://www.prnewswire.com/news-releases/ucbs-cimzia-is-making-inroads-in-the-treatment-of-axial-disease-with-significant-uptake-in-non-radiographic-axial-spondyloarthritis-and-a-positive-treatment-halo-in-ankylosing-spondylitis-301048947.html
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-2020
https://www.fiercepharma.com/pharma/enbrel-patent-appeal-from-sandoz-amgen-appears-favorite-analyst
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103795
https://www.businesswire.com/news/home/20191230005088/en/Clover-Biopharmaceuticals-Initiates-Phase-III-Study-Etanercept
https://www.fiercepharma.com/pharma/after-ftc-surprises-what-antitrust-scrutiny-should-biopharma-expect-their-m-a-deals-2020
https://www.fiercepharma.com/pharma/amgen-snags-another-enbrel-outcomes-payment-deal-as-it-seeks-to-prop-up-aging-blockbuster
https://www.fiercepharma.com/pharma/yes-amgen-overpaid-for-otezla-but-doesn-t-make-it-a-mistake-analysts
https://www.fiercepharma.com/marketing/amgen-puts-out-welcome-mat-for-celgene-s-otezla-reps-but-will-they-join-and-then-stay
https://www.amgen.com/media/news-releases/2019/08/amgen-to-acquire-otezla-for-134-billion-in-cash-or-approximately-112-billion-net-of-anticipated-future-cash-tax-benefits/
https://endpts.com/the-top-10-franchise-drugs-in-biopharma-history-will-earn-a-total-of-1-4t-trillion-by-2024-what-does-that-tell-us/
https://endpts.com/the-key-dates-for-kras-watchers-through-the-end-of-the-year-the-trail-is-narrow-and-risks-are-extreme/?utm_medium=email&utm_campaign=790%20Friday%20August%2016%20-%206%20years%20after%20Sanofi%20killed%20it%20fedratinib%20wins%20FDA%20OK%20Top%2010%20franchise%20drugs%20in%20history%20offer%2014T%20lesson&utm_content=790%20Friday%20August%2016%20-%206%20years%20after%20Sanofi%20killed%20it%20fedratinib%20wins%20FDA%20OK%20Top%2010%20franchise%20drugs%20in%20history%20offer%2014T%20lesson+CID_0faf5d59b692c300e4ef716e0fddccee&utm_source=ENDPOINTS%20emails&utm_term=The%20key%20dates%20for%20KRAS%20watchers%20through%20the%20end%20of%20the%20year%20%20the%20trail%20is%20narrow%20and%20risks%20are%20extreme
https://www.raps.org/news-and-articles/news-articles/2019/8/amgen-wins-enbrel-patent-suit-preventing-sandoz-bi
https://www.cnbc.com/2019/08/09/reuters-america-update-1-amgen-wins-u-s-patent-battle-on-arthritis-drug-enbrel-thwarting-novartis.html
https://www.biospectrumasia.com/news/25/14104/takeda-pfizer-terminate-co-promotion-of-ra-drug-enbrel.html
https://www.statnews.com/2019/07/30/drug-prices-social-contract-pharma-leaders/
https://www.fiercepharma.com/pharma/crowded-psoriasis-who-could-pick-up-bristol-celgene-s-otezla-at-what-price
https://endpts.com/the-washington-post-points-the-finger-at-pfizer-for-staying-mum-about-an-alzheimers-study-but-theres-more-to-the-story-than-that/
https://www.business-standard.com/article/pti-stories/lupin-receives-eu-gmp-certificate-for-mammalian-facility-in-pune-119032700366_1.html
http://www.fdalawblog.net/2019/05/and-if-they-dont-dance-well-theyre-no-friends-of-mine-and-theyll-probably-get-sued/
Market Place
Share 
